Arrowhead Pharmaceuticals: Strong Market Position and Growth Potential with REDEMPLO’s FDA Approval

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Arrowhead Pharmaceuticals. The associated price target remains the same with $80.00.

Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Arrowhead Pharmaceuticals’ strong position in the market. The recent FDA approval of REDEMPLO (plozasiran) as the first siRNA therapy for familial chylomicronemia syndrome (FCS) is a significant milestone. This approval is notable for its best-in-class profile, including quarterly at-home dosing, no contraindications, and applicability to both genetically confirmed and clinically diagnosed FCS patients. The Phase 3 trial results demonstrated an unprecedented median triglyceride reduction of approximately 80%, with a clean safety profile, which further strengthens its market potential.
Additionally, the strategic launch preparations and payer interactions covering a substantial portion of U.S. lives position REDEMPLO as a foundational product in the rare-disease market. The One-REDEMPLO pricing strategy is expected to anchor long-term value, particularly in the high-risk severe hypertriglyceridemia (sHTG) segment. With upcoming Phase 3 trial data expected in the third quarter of 2026, Arrowhead Pharmaceuticals is well-positioned for a multi-year expansion cycle, further justifying the Buy rating and the $80 price target.